Realcan Pharmaceutical Group announced that the company intends to jointly invest with MeiYiTian Biomedical (Wuhan) Co., Ltd. to establish a joint venture company to jointly build a base for the development of human intestinal microbial function mining and clinical application technology. The total investment of the joint venture company is expected to be 10 million yuan.
瑞康医药：拟1000万元设合资公司 共建人体肠道微生物功能挖掘及临床应用技术开发基地
Realcan Pharmaceutical Group plans to establish a joint venture company with a capital of 10 million yuan to jointly build a base for the development of human intestinal microbial function mining and clinical application technology.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.